Catalent, Inc. (CTLT) Receives $42.13 Average Target Price from Analysts
Catalent, Inc. (NYSE:CTLT) has received a consensus recommendation of “Buy” from the thirteen research firms that are presently covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $42.13.
CTLT has been the topic of a number of research analyst reports. Bank of America reaffirmed a “buy” rating and issued a $40.00 price target (up from $38.00) on shares of Catalent in a research note on Tuesday, August 29th. BidaskClub raised Catalent from a “hold” rating to a “buy” rating in a research note on Friday, September 8th. ValuEngine raised Catalent from a “hold” rating to a “buy” rating in a research note on Thursday, September 7th. J P Morgan Chase & Co reaffirmed a “buy” rating and issued a $40.00 price target on shares of Catalent in a research note on Tuesday, August 29th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $45.00 price target on shares of Catalent in a research note on Tuesday, August 29th.
In related news, Director Uwe Roehrhoff acquired 7,500 shares of Catalent stock in a transaction that occurred on Tuesday, November 21st. The shares were purchased at an average price of $39.22 per share, for a total transaction of $294,150.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.70% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio raised its position in Catalent by 1,441.4% in the third quarter. Public Employees Retirement System of Ohio now owns 41,156 shares of the company’s stock valued at $1,643,000 after purchasing an additional 38,486 shares during the period. GSA Capital Partners LLP raised its position in Catalent by 59.0% in the third quarter. GSA Capital Partners LLP now owns 52,972 shares of the company’s stock valued at $2,115,000 after purchasing an additional 19,661 shares during the period. Iguana Healthcare Management LLC purchased a new stake in Catalent in the third quarter valued at $1,198,000. Colony Group LLC purchased a new stake in Catalent in the third quarter valued at $2,543,000. Finally, Neuberger Berman Group LLC raised its position in Catalent by 77.3% in the third quarter. Neuberger Berman Group LLC now owns 23,025 shares of the company’s stock valued at $919,000 after purchasing an additional 10,036 shares during the period. Hedge funds and other institutional investors own 99.44% of the company’s stock.
Shares of Catalent (NYSE:CTLT) traded down $1.00 on Friday, reaching $39.41. The company’s stock had a trading volume of 809,700 shares, compared to its average volume of 914,885. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.49 and a current ratio of 2.91. Catalent has a one year low of $22.94 and a one year high of $43.39. The firm has a market capitalization of $5,290.00, a price-to-earnings ratio of 27.61, a P/E/G ratio of 2.54 and a beta of 1.49.
Catalent (NYSE:CTLT) last issued its quarterly earnings data on Monday, November 6th. The company reported $0.21 EPS for the quarter, beating the consensus estimate of $0.20 by $0.01. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The company had revenue of $543.90 million for the quarter, compared to analyst estimates of $490.75 million. During the same period last year, the company earned $0.16 earnings per share. Catalent’s quarterly revenue was up 23.0% compared to the same quarter last year. analysts anticipate that Catalent will post 1.46 earnings per share for the current fiscal year.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.